January 29, 2021 07:27 AM EST

The diabetes 'cure' Vertex acquired in its 2019 Semma buyout? It's headed to the clinic

Max Gelman

Senior Editor

The stem cell-derived therapy at the center of Vertex’s $950 million buyout of Semma Therapeutics in 2019, one that features prominently in the company’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

The diabetes 'cure' Vertex acquired in its 2019 Semma buyout? It's headed to the clinic

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Gilead buys experimental HIV vaccines from a small Barcelona biotech

The di­a­betes 'cure' Ver­tex ac­quired in its 2019 Sem­ma buy­out? It's head­ed to the clin­ic

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

The diabetes 'cure' Vertex acquired in its 2019 Semma buyout? It's headed to the clinic

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Gilead buys experimental HIV vaccines from a small Barcelona biotech